Despite a solid market, these stocks fell. Find out why.
News & Analysis: OncoMed Pharmaceuticals
A failed clinical trial and a lost partner make for a bad Monday.
The development-stage biotech raises capital, diluting shareholders in the process.
The biotech's shares sank after independent investigators reported that the company's experimental pancreatic cancer drug appears destined to miss its study goals in an ongoing midstage trial.
Annual global cancer incidence rates are expected to rise by nearly 60% in the next 20 years, prompting drug developers to get creative in their fight against cancer.
Years from now this new study may change the way pharmaceutical companies and physicians fight cancer.
Pancreatic cancer is the fourth-leading cause of cancer-related death, but researchers may have moved one step closer to discovering a cure this past week.
Three biotechs climb after a competitor's trial success boosts hope across the HER-2 breast cancer treatment market
OncoMed shares reverse course from Friday's swoon despite the release of mixed news from the company.
Five clinical updates that made waves in the biotech sector this week, as well as the surprising buyout that still has Wall Street abuzz.